My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$RSG {{ '2016-03-04T20:02:16+0000' | timeago}} • SEC

$RSG's revenue for the year ended December 31, 2015 increased by 3.5% to $9.1Bil. Pretax income was $1.19Bil in 2015. Net income attributable to $RSG was $749.9MM or $2.13 per diluted share for 2015 compared to $547.6MM or $1.53 per diluted share for 2014. $RSG expects 2016 revenue to increase by approx. 2.5-3%.

User Vishnu Beri {{ '2016-10-25T21:15:45+0000' | timeago}}

Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

$KO {{ '2016-10-26T13:21:34+0000' | timeago}} • Webcast

$KO's core business performed well with a 4% organic revenue growth YTD, in line with the company's long term target. Additionally, within the core business, developed markets performed well, with a YTD unit case volume growth of 2%.

$MDLZ {{ '2016-10-26T13:21:06+0000' | timeago}} • Announcement

Food and confectionery giant $MDLZ reported a 3Q16 profit of $0.35, down 92% due to prior year's $7Bil gain related to the company's coffee business transactions. Net revenues decreased 6.6% to $6.4Bil.

$BIIB {{ '2016-10-26T13:15:56+0000' | timeago}} • Webcast

$BIIB's Tysabri worldwide revenue was $515MM in 3Q16, an increase of 7% versus last year. This included $301MM in the US and $214MM outside the US. Tysabri revenue outside the US benefited by $20MM, due to a favorable adjustment to the company's discounts in allowances. ForEx and the hedge impact weakened Tysabri sales by approx. $16MM versus 3Q15.

$CMCSA {{ '2016-10-26T13:13:33+0000' | timeago}} • Webcast

$CMCSA's consolidated Capex increased 11.1% to $2.4Bil in 3Q16. During 3Q16, the company paid dividends totaling $663MM and repurchased 20.8MM of its common shares for $1.4Bil.

$BIIB {{ '2016-10-26T13:13:06+0000' | timeago}} • Webcast

$BIIB stated that Interferon revenues, including both Avonex and Plegridy, were $708MM during 3Q16, a decrease of 10% versus last year. This included $506MM in the US and $203MM in sales outside the US. In the US, there was a drawdown of Avonex inventory in the wholesale channel, resulting approx. $10MM versus 2Q16.